Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Sitbon, M. Beghetti, J. Petit, L. Iserin, M. Humbert, V. Gressin, G. Simonneau (Clamart, Le Plessis Robinson, Paris, France; Geneva, Switzerland). The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD). Eur Respir J 2004; 24: Suppl. 48, 4331

Member's Comments

No comment yet.

Related content which might interest you: Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study Source: ERJ Open Res, 4 (3) 00060-2018; 10.1183/23120541.00060-2018 Year: 2018 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005